Combining ASA404 with Carboplatin and Paclitaxel for Lung Cancer
Author Information
Author(s): McKeage M J, Von Pawel J, Reck M, Jameson M B, Rosenthal M A, Sullivan R, Gibbs D, Mainwaring P N, Serke M, Lafitte J-J, Chouaid C, Freitag L, Quoix E
Primary Institution: University of Auckland
Hypothesis
Can ASA404 combined with carboplatin and paclitaxel improve outcomes in patients with advanced non-small cell lung cancer?
Conclusion
The study shows that combining ASA404 with carboplatin and paclitaxel is feasible and may improve survival in patients with advanced non-small cell lung cancer.
Supporting Evidence
- The addition of ASA404 improved median survival from 8.8 months to 14.0 months.
- Tumour response rates were higher in the ASA404 group (31%) compared to the control group (22%).
- The safety profiles of both treatment groups were similar, with manageable adverse effects.
Takeaway
This study tested a new drug called ASA404 with standard cancer treatments to see if it helps people with lung cancer live longer. It looks like it might help!
Methodology
Patients were randomly assigned to receive either standard therapy or standard therapy plus ASA404, and their responses were measured over several cycles of treatment.
Potential Biases
Potential bias in patient selection and assessment of outcomes due to the open-label design.
Limitations
The study was not powered to compare efficacy outcomes statistically, and the sample size was relatively small.
Participant Demographics
Patients were men and women aged 18 and older with advanced non-small cell lung cancer, with a mix of histological subtypes.
Statistical Information
P-Value
0.33
Confidence Interval
95% CI 0.39, 1.38
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website